HOUSTON, Nov. 19, 2019 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology
company specializing in the development of novel treatments for
brain tumors, completed an agreement with Houston Pharmaceuticals,
Inc. ("HPI") to obtain the rights to a worldwide, exclusive
royalty-bearing, license for the chemical compound commonly known
as Berubicin.
CNS' licensing agreement with HPI grants the Company the
exclusive right to develop certain patented chemical compounds for
use in the treatment of cancer globally. In its agreement with HPI,
the Company acquired multiple U.S. patents for Berubicin. CNS
intends to apply for orphan drug status for Berubicin with the FDA
for the treatment of malignant glioma.
"We believe our acquisition of the rights to Berubicin
represents an important milestone in our pursuit to develop
therapies for the treatment of glioblastoma, a type of brain cancer
which is currently considered incurable," stated CEO of CNS,
John M. Climaco, Esq. "Our agreement
with HPI expands our IP protection and provides us with
developmental protection worldwide while we seek orphan drug
status. We are excited to continue the clinical development of
Berubicin and believe its promising tolerability and efficacy
results are a testament to its therapeutic potential as a novel
anthracycline agent."
About Berubicin
Berubicin is an anthracycline, a class
of drugs among the most powerful chemotherapy drugs and effective
against more types of cancer than any other class of
chemotherapeutic agents. Anthracyclines are designed to damage the
DNA of targeted cancer cells by interfering with the action of the
topoisomerase II, a critical enzyme enabling cell proliferation.
Berubicin was developed at the MD Anderson Cancer Center (MDACC),
the world's largest cancer research facility. Berubicin appeared to
demonstrate one Durable Complete Response in a Phase I human
clinical trial conducted by a prior developer.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is
a biotechnology company specializing in the development of novel
treatments for primary and metastatic brain and central nervous
system tumors. Its lead candidate Berubicin is for the treatment of
glioblastoma, a type of brain cancer currently considered
incurable, as well as pancreatic and ovarian cancers, and
lymphomas. The Company entered into an IP agreement with Houston
Pharmaceuticals, Inc. and a Purchase Agreement with Reata
Pharmaceuticals Inc. For more information, visit
www.cnspharma.com.
Forward-Looking Statements
Some of the statements in
this release are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. Forward-looking statements in this press release
include, without limitation, the ability of CNS to apply for and
receive orphan drug status for Berubicin. These statements relate
to future events, future expectations, plans and prospects.
Although CNS believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
CNS has attempted to identify forward-looking statements by
terminology including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under in our SEC filings, including under the heading "Risk
Factors" in the Form S-1 we filed with the SEC on October 7, 2019. Any forward-looking statements
contained in this release speak only as of its date. CNS undertakes
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-acquired-worldwide-rights-for-brain-cancer-drug-from-houston-pharmaceuticals-300960582.html
SOURCE CNS Pharmaceuticals, Inc.